118P - A retrospective comparison of eribulin and capecitabine in patients with HER2-negative metastatic breast cancer

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Breast Cancer, Metastatic
Presenter Natsuko Tsushita
Citation Annals of Oncology (2016) 27 (suppl_9): ix35-ix41. 10.1093/annonc/mdw577
Authors N. Tsushita1, T. Shimoi1, H.S. Okuma1, A. Kawachi1, A. Kitano1, T. Nishikawa1, A. Shimomura1, E. Noguchi1, M. Kodaira2, M. Yunokawa1, K. Yonemori1, C. Shimizu1, Y. Fujiwara1, K. Tamura1
  • 1Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2Medical Oncology, JIKOKAI Kodaira Hospital, 330-0052 - Toda/JP



Eribulin (ERI) is one of the standards of care in metastatic breast cancer (MBC) after anthracycline and taxane. In 301 trial, overall survival of ERI was comparable to that of capecitabine (CAP), though this trial failed to show the superiority of ERI over CAP. In the real world clinical practice, choice of ERI or CAP is a challenging problem. This study retrospectively compared ERI and CAP.


The inclusion criteria were HER2-negative MBC patients treated with ERI and/or CAP between 2011 and 2015 after anthracycline and taxane. Overall response rate (ORR) was defined as the rate of CR and PR. Time to progression (TTP) was defined as a period from the initiation of ERI or CAP to PD or death. We analyzed ORR and TTP of ERI and CAP. We defined E group as the patients who received ERI only or who received ERI before CAP. We also defined C group as the patients who received CAP only or who received CAP before ERI. Median survival time (MST) of E group/C group was defined as the median time from ERI/CAP administration to death. We compared MST of E and C groups by treatment lines.


A total of 182 patients were included. The number of patients in E group/C group was 77/113. The median age of E group/C group was 57 [34-75]/59 [30-79] years. The proportion of triple negative breast cancer in E group/C group was 28.6/14.2%. The crossover rate of E group/C group was 39.0/75.7% (p 


ORR of ERI was comparable to that of CAP, whereas TTP of ERI was shorter than CAP. MST was longer in C group than E group when compared in the same treatment lines. The inferiority of E group might reflect that fewer patients in E group were treated with CAP after failure of ERI. Reasons for the less crossover rate in E group should further be analyzed. Investigating specific subgroups for which one drug is more effective than the other will be the next step of our research.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.